Cardiometabolic Panel (ApoB, Lp(a), HbA1c, Fasting Insulin) - References

Cardiometabolic Panel (ApoB, Lp(a), HbA1c, Fasting Insulin) — Literature Dossier

Navigation

• Backed Topic Note: Cardiometabolic Panel (ApoB, Lp(a), HbA1c, Fasting Insulin)
• References Hub: 03 - Diagnostics & Quantified Self References MOC
• Parent Silo MOC: 03 - Diagnostics & Quantified Self MOC

---

Landmark Peer-Reviewed Studies

1. Sniderman et al. (2019) — ApoB as the Primary Determinant of Atherogenic Risk

• Citation: Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019). Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology, 4(12), 1287–1295.
• Identifiers: DOI: 10.1001/jamacardio.2019.3780 (DOI · SciDB · Scholar) | PMID: 31642874 (PubMed · Europe PMC) | PMCID: PMC7269165 (PMC Full Text)
• Study Design & Cohort: Comprehensive synthesis of prospective discordance cohorts (Framingham Offspring, CARDIA, Women’s Health Study, INTERHEART, UK Biobank; combined $N>400,000$) and Mendelian randomization analyses comparing LDL-C, non-HDL-C, and ApoB.
• Quantitative Findings & Diagnostic Thresholds:
  • When ApoB and LDL-C are discordant, cardiovascular risk consistently tracks with ApoB ($\text{HR }1.24–1.38$ per 1-SD increment in ApoB) and not LDL-C.
  • Mendelian randomization comparing CETP and HMGCR variants demonstrated that clinical benefit is proportional to absolute reduction in ApoB ($\text{OR }0.78$ per $30\text{ mg/dL}$ ApoB reduction), regardless of LDL-C or HDL-C changes.

2. Ference et al. (2017) — Causal Cumulative Exposure to ApoB Lipoproteins

• Citation: Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., … & Catapano, A. L. (2017). Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. European Heart Journal, 38(32), 2459–2472.
• Identifiers: DOI: 10.1093/eurheartj/ehx144 (DOI · SciDB · Scholar) | PMID: 28444290 (PubMed · Europe PMC) | PMCID: PMC5837225 (PMC Full Text)
• Study Design & Cohort: Meta-analysis of $>200$ prospective cohort studies, Mendelian randomization studies, and randomized controlled trials totaling $>2,000,000$ participants with $>20,000,000$ person-years of follow-up and $>150,000$ cardiovascular events.
• Quantitative Findings & Diagnostic Thresholds:
  • Log-linear dose-dependent association between cumulative ApoB/LDL exposure and ASCVD risk: each $1\text{ mmol/L}$ ($38.7\text{ mg/dL}$) lower LDL-C via genetic variants confers a 54.5% reduction in coronary heart disease risk ($\text{OR }0.455$, $95\%\text{ CI }0.42–0.49$), versus a 22% reduction ($\text{HR }0.78$) over 5-year statin trials, proving the plaque burden model of cumulative lifetime ApoB exposure.

3. Patel et al. (2021) — Lipoprotein(a) Continuous Hazard Curve in UK Biobank

• Citation: Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V. (2021). Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank. Arteriosclerosis, Thrombosis, and Vascular Biology, 41(1), 465–474.
• Identifiers: DOI: 10.1161/ATVBAHA.120.315291 (DOI · SciDB · Scholar) | PMID: 33115266 (PubMed · Europe PMC) | PMCID: PMC7770058 (PMC Full Text)
• Study Design & Cohort: Prospective cohort study in the UK Biobank ($N=460,506$ middle-aged adults followed for median 11.2 years).
• Quantitative Findings & Diagnostic Thresholds:
  • Linear hazard gradient starting above optimal baseline ($<20–30\text{ nmol/L}$): each $50\text{ nmol/L}$ increment in Lp(a) conferred a multivariable-adjusted $\text{HR of }1.11$ ($95\%\text{ CI }1.10–1.12$) for incident ASCVD.
  • Individuals with $\text{Lp(a)}\ge 150\text{ nmol/L}$ had an adjusted $\text{HR of }1.50$ ($95\%\text{ CI }1.44–1.56$) in primary prevention and $\text{HR }1.23$ in secondary prevention.

4. Selvin et al. (2010) — Glycated Hemoglobin (HbA1c) and Vascular/Mortality Risk in Non-Diabetics

• Citation: Selvin, E., Steffes, M. W., Zhu, H., Matsushita, K., Wagenknecht, L., Pankow, J., … & Brancati, F. L. (2010). Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. New England Journal of Medicine, 362(9), 800–811.
• Identifiers: DOI: 10.1056/NEJMoa0908359 (DOI · SciDB · Scholar) | PMID: 20200384 (PubMed · Europe PMC) | PMCID: PMC2872990 (PMC Full Text)
• Study Design & Cohort: Prospective cohort from the Atherosclerosis Risk in Communities (ARIC) study ($N=11,092$ adults without a history of diabetes or cardiovascular disease; 15-year median follow-up).
• Quantitative Findings & Diagnostic Thresholds:
  • Compared to reference optimal HbA1c of $5.0\text{ to }<5.5\%$:
    • HbA1c $5.5\text{ to }<6.0\%$: Coronary heart disease $\text{HR }1.23$ ($95\%\text{ CI }1.07–1.41$); all-cause mortality $\text{HR }1.14$.
    • HbA1c $6.0\text{ to }<6.5\%$: Coronary heart disease $\text{HR }1.78$ ($95\%\text{ CI }1.48–2.15$); ischemic stroke $\text{HR }2.31$; all-cause mortality $\text{HR }1.59$.

5. Ausk et al. (2010) — HOMA-IR and All-Cause/Cardiovascular Mortality in NHANES

• Citation: Ausk, K. J., Boyko, E. J., & Ioannou, G. N. (2010). Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care, 33(6), 1179–1185.
• Identifiers: DOI: 10.2337/dc09-2110 (DOI · SciDB · Scholar) | PMID: 20200308 (PubMed · Europe PMC) | PMCID: PMC2875419 (PMC Full Text)
• Study Design & Cohort: Nationally representative prospective cohort from NHANES III ($N=5,511$ non-diabetic US adults followed up to 12 years).
• Quantitative Findings & Diagnostic Thresholds:
  • Non-diabetic adults in the top quartile of HOMA-IR ($>2.8$) vs. lowest quartile ($\text{HOMA-IR }\le 1.4$, corresponding to fasting insulin $<5.5\mu \text{IU/mL}$) exhibited a multivariable-adjusted all-cause mortality $\text{HR of }1.64$ ($95\%\text{ CI }1.1–2.5$), establishing fasting hyperinsulinemia as an independent mortality driver prior to glycemic decompensation.